+34 620 10 75 37info@nanbiosis.com

Nanbiosis

You are here : Home / 2024

NANBIOSIS in the CIBER Conference in Valencia

NANBIOSIS will showcase its services and present the Chips R’ Us project at the 10th Anniversary CIBER Conference in Valencia, Nov 27-30, 2024.

Valencia, november 2024. In cellebration of the 10th anniversary of the CIBER network, CIBER is organizing a special edition of its Scientific Conference 2024, which will take place in Valencia on November 27-30, 2024. This prestigious event, which is expected to gather over 1500 researchers, clinicians, and key stakeholders in biomedical innovation, serves as a vital platform for presenting cutting-edge scientific achievements and fostering collaborations within the Spanish research ecosystem.

This year, NANBIOSIS will have a significant presence at the conference. We will activelly participate in the organization of the event, demonstrating our continued commitment to advancing biomedical research through innovation and collaboration.

NANBIOSIS at the Conference

During the conference, NANBIOSIS will showcase its services and capabilities at a dedicated stand, shared with other leading scientific platforms. This joint exhibition aims to highlight the synergies and resources available within the Spanish scientific community, promoting the integration of multidisciplinary approaches to address complex biomedical challenges.

In addition to its presence at the stand, NANBIOSIS will also take center stage during the closing session of the conference, where Chips R’ Us, a pioneering project coordinated by the platform, will be presented. This project, in which four different CIBER platforms participate (CIBER-BBN, CIBERES, CIBER-INFEC and CIBER-ONC), exemplifies the innovative research fostered by NANBIOSIS and its impact on translational medicine.

The CHIPS R’ US project aims to improve the study and treatment of Lower Respiratory Tract Infections (LRTI), a leading cause of child mortality. The project aims to replicate a realistic lung microenvironment using Organ-on-chip technology. This approach allows precise emulation of respiratory conditions and enables real-time monitoring with advanced imaging tools. Coordinated by NANBIOSIS, the project fosters collaboration across four CIBER areas (BBN, ES, INFEC, ONC) and lays the groundwork for future interdisciplinary initiatives.

Solidarity and Commitment: CIBER Stands with Valencia

As stated by the organization of the event: “We express our solidarity with Valencia and its residents following the effects of the DANA and confirm that the congress will proceed as planned, reaffirming our commitment to scientific development”. The webpage of the conference also stated that “We firmly believe that moving forward with the CIBER Congress is our best way to support the Valencian Community while maintaining our commitment to the scientific community and society at large.”

A Key Venue for Biomedical Innovation

The conference program includes a mix of plenary sessions, round tables, poster presentations, and networking activitis, covering diverse areas such as personalized medicine, advanced therapies, and health technology. By bringing together experts from various disciplines, the event creates opportunities for the exchange of ideas and the development of groundbreaking solutions to improve patient care.

NANBIOSIS invites all attendees to visit its stand to learn more about its state-of-the-art services and to attend the closing session to discover the outcomes of Chips R’ Us. As a key participant in this 10th Anniversary CIBER Scientific Conference, NANBIOSIS reaffirms its position as a leader in enabling high-impact biomedical research.

For more information about the event, please visit the CIBER Annual Scientific Conference website.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

The Protein Production Platform (PPP) at the UAB Innovation Fair

The PPP advances antimicrobial peptide research, forging partnerships to combat antibiotic resistance and prevent medical device-related infections.

Barcelona, october 2024. During Antibiotic Awareness Week, we spotlight the Protein Production Platform (PPP) at NANBIOSIS Unit 1 for its pivotal role in combating antimicrobial resistance.

At the recent UAB Innovation Fair, the PPP showcased its cutting-edge technologies and established collaborations with experts in bacterial biofilms and nanomaterials. Together, they aim to develop innovative antimicrobial peptides as alternatives to traditional antibiotics, targeting nosocomial infections linked to medical devices. These efforts underscore the critical importance of advancing research and partnerships to address one of the greatest global health challenges: antibiotic resistance.

Protein Production Platform at the UAB Innovation Fair

Las month, our Unit 1, also known as Protein Production Platform (PPP), participated in the second edition of the UAB Innovation Fair, held at the Autonomous University of Barcelona (UAB). The event served as a vibrant meeting point for research groups, spin-offs, and companies, all focused to explore potential synergies and collaborative opportunities.

The fair provided an excellent platform for the PPP to showcase its capabilities and services. During the event, our Unit established valuable contacts with several diagnostic companies and protein research groups. These interactions not only highlighted the potential benefits these entities could gain from our services, but also opened the door to collaborations that could further enhance the platform’s offerings.

In addition to these interactions, the PPP, as part of the Nanobiotechnology (NBT) research group, connected with specialists in bacterial biofilms and nanomaterials. These experts expressed interest in collaborating on our research focused on antimicrobial peptides aimed at developing alternatives to traditional antibiotics, with the goal of preventing nosocomial infections associated with medical devices.

The PPP’s active participation in the UAB Innovation Fair not only highlights its commitment to advancing scientific research but also demonstrates its dedication to creating impactful partnerships. By engaging with a diverse array of stakeholders, the PPP is well-positioned to drive forward innovative solutions and contribute to the broader scientific community.

The fair was a resounding success, providing a dynamic environment for knowledge exchange and collaboration. The PPP looks forward to building on the connections made during the event and continuing to play a crucial role in the advancement of protein production technologies, nanobiotechnology research, as well as the ongoing battle against antimicrobial resistance.

A few pictures of the Unit 1 leaders and collaborators during the event.

The Protein Production Platform (PPP), also known as NANBIOSIS Unit 1, specializes in the production, purification, and characterization of recombinant proteins and biomaterials. It leverages state-of-the-art technologies to support biomedical and nanotechnology research, focusing on applications such as cancer treatment, antimicrobial resistance, and advanced protein delivery systems. Operated by the Nanobiotechnology Group at the Autonomous University of Barcelona, it serves academic and industrial clients with customized solutions for protein engineering and synthesis.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

European Partnership Opens a New Era in Rare Disease Research

The European Rare Diseases Research Alliance (ERDERA) kicked off last month, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond.

Paris, october 2024. The European Rare Diseases Research Alliance (ERDERA), a new initiative under Horizon Europe, has officially launched with an ambitious mission to improve the lives of 30 million people affected by rare diseases across Europe and beyond.

Backed by a budget of €380 million, ERDERA brings together more than 170 organizations from the public and private sectors, led by the National Institute of Health and Medical Research (INSERM) in France. This collaborative effort aims to advance research on prevention, diagnosis, and treatment for rare diseases, creating a robust infrastructure for innovation and patient support.

ERDERA’s focus is to build on the successes of previous projects, such as the European Joint Programme on Rare Diseases (EJP RD) and the SOLVE-RD project. It strives to create a seamless network of resources and expertise, fostering a globally competitive European research area for rare diseases.

NANBIOSIS participation in ERDERA

CIBER-BBN group led by Ramón Martínez, director of NANBIOSIS and Scientific Director of our Unit 26, together with Juan Antonio Bueren’s group (CIBERER), will participate in a work package aimed at accelerating key technologies in the field of advanced therapies. Specifically, these two CIBER areas will develop new gene and gene-editing therapies, both viral and non-viral, for rare diseases affecting hematopoietic, epidermal, inflammatory, and metabolic disorders. They will employ in vitro and in vivo approaches, as well as lipid nanoparticles for the encapsulation and controlled release of mRNA.

Unit 26 specializes in Nuclear Magnetic Resonance (NMR) technology, providing valuable capabilities for acquiring unique metabolic profiles from a variety of biological samples, including biofluids, cell lines, tissues, and animal models such as mice and rats.

This expertise is crucial in uncovering molecular markers that can help researchers better understand rare diseases, ultimately contributing to the development of more precise diagnostic and therapeutic strategies.

NANBIOSIS Unit 26’s NMR capabilities complement ERDERA’s clinical research network, which aims to accelerate diagnostics and increase clinical trial readiness for rare diseases. The alliance’s comprehensive support services, including a Data Services Hub and an Expertise Services Hub, will benefit from the detailed metabolic profiling provided by Unit 26, further strengthening the infrastructure available to researchers.

Daria Julkowska, ERDERA’s scientific coordinator, highlighted the alliance’s vision of integrating cross-disciplinary expertise under a unified mission: “We have a tripartite mission: One; to bring under one roof a broad range of high-value services, resources and cross-disciplinary expertise to support rare disease research; Two, to boost clinical research by enabling every consenting patient living with a rare disease to be findable and enrolled in a suitable clinical study and finally, to spur innovation and EU competitiveness, through investment but also by aligning regional, national and European research strategies, and fostering collaboration among all stakeholders at a global scale.”

ERDERA’s roadmap, presented during its launch event on 28 October 2024, underscores the importance of collaborations with specialized research infrastructures like NANBIOSIS. Together, these efforts aim to bridge gaps in diagnosis and treatment for rare diseases, transforming the landscape of patient care in Europe.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

The Soft Lab held a new edition of the course on characterization and preparation of particulate materials

José Amable Bernabé, Technical Coordinator of Unit 6, hosted a course on “Characterization techniques for particulate materials”.

Barcelona, october 2024. For yet another year, José Amable Bernabé, of the Soft Materials Service at ICMAB and Technical Coordinator of NANBIOSIS Unit 6, offered this course. The course was an explanation of different techniques to characterize nanoparticles and particulate matter, including the fundamentals of these techniques, sample preparation, practical examples and results interpretation.

The course is offered every year through the CSIC training courses offered every year for all its staff, as reported in ICMAB webpage.

Soft Materials Service

The Soft Materials Service provides equipment and technical assistance for the preparation and characterization of micro-and nanostructured soft molecular materials (molecular surfaces, micro- and nanoparticulate molecular materials, plastic films, dispersed systems, SAMs, etc..) with interest in different areas of application (biomedicine, electronics, energy storage and other chemical and material application areas).

The Soft Materials Service, with Amable Bernabé and David Piña as technicians, participate in many European projects and give service to the whole ICMAB community, apart from the Nanomol Research Unit, and also to other CSIC centers and research institutions and companies.

On April 2022, the Service Materials Service, which is part of our Unit 6, obtained the ISO 9001:2015 Quality Certification, which ensures the quality of the service provided and helps to continue with its improvement and extension to future services.

Amable Bernabé showing the materials' characterization equipment to the course participants
Amable Bernabé showing the materials’ characterization equipment to the course participants. Source: ICMAB webpage.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

attendants of the course held at ICMAB
• Read More

A project on pediatric respiratory infections, led by NANBIOSIS, wins the CIBER Young Researcher Call

Chips R’ Us, a pediatric respiratory infection study, wins CIBER’s Young Researcher Call, developing an innovative lung model using Organ-on-Chip technology.

Vigo, october 2024. The project Chips R’ Us, focused on studying lower respiratory infections in pediatric patients, has been selected in the 2024 Call for Intramural Projects for Young Researchers of the Biomedical Research Networking Center (CIBER). An evaluation board composed of specialists from various CIBER thematic areas evaluated the proposals based on their novelty, feasibility, interdisciplinary collaboration, and potential social impact.

Led by Dr. Gabriel Alfranca, a researcher in the area of Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN) at the Interuniversity Research Institute for Molecular Recognition and Technological Development, and developed in collaboration with NANBIOSIS-ICTS, the project will receive €5,000 in funding. The project will be presented at the CIBER Congress, which will be held in Valencia from November 27 to 29 this year 2024.

“We want to create a model capable of replicating lung conditions, especially for the most vulnerable patients. If we succeed, this device could be applied in the future not only for therapies in children but for any other respiratory disease“

— Dr. Gabriel Alfranca

The initiative aims to develop an innovative in vitro model using an Organ-on-Chip (OoC) device that simulates the microenvironment of the human lung. Through human alveolar epithelial cells (HPAEpiC) exposed to nasopharyngeal samples from both healthy pediatric patients and those with bronchiolitis, cellular responses to various stimuli can be observed in real-time. “We want to create a model capable of replicating lung conditions, especially for the most vulnerable patients. If we succeed, this device could be applied in the future not only for therapies in children but for any other respiratory disease,” says Dr. Alfranca.

The collaboration of CIBER-BBN with CIBER’s Infectious Diseases (CIBERINFEC), Cancer (CIBERONC), and Respiratory Diseases (CIBERES) areas strengthens the proposal, with NANBIOSIS-ICTS playing a key role in manufacturing the device. The device will include advanced sensors and image analysis through artificial intelligence, enabling detailed monitoring of cellular changes and opening new possibilities for diagnosing and treating respiratory diseases.

With the support of the funding, Gabriel Alfranca’s team (formed by Carlos Castilla, Denise Marrero, Marta Camprubí and Sonia Alcolea) will have one year to develop the project, with the expectation that it will lay the foundation for future larger-scale research, particularly in the field of personalized medicine and the development of advanced diagnostic platforms.

The Chirs R Us project is an inter-area between CIBER groups. This includes the participation of our Unit 8 from CIBER-BBN. Leading the project is Dr. Gabriel Alfranca, member of the coordination team of NANBIOSIS.

Team members of the finalist teams, Chips R’ Us, Trientech and KKs6, as well as the organization team of the award during the Congress for Young Scientific Researchers in Vigo.

First Congress for Young Scientific Researchers in Vigo

During the First CIBER Congress for Young Scientific Researchers, held in Vigo in June 2024, participants were encouraged to engage in a networking activity that could lead to a collaborative project idea. In addition to Chips R’ Us, two other finalist projects, Trientech and KKs6, were recognized for their innovation and quality. However, Chips R’ Us stood out for its multidisciplinary approach, involving collaboration between various CIBER areas, and its potential to develop a model with significant clinical impact in the personalized treatment of respiratory infections.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

U18-S05. Histological analyses

Histological analyses

The aim of this service is to evaluate the toxicity or antitumor activity of nanoparticles and drug-loaded nanoparticles in normal or tumor tissues provided by the customer or obtained in the in vivo assays performed in the unit. The histological analyses that we offer include hematoxylin&eosin staining to evaluate the toxicity in normal tissues and also the mitotic index or cell death present in tumor tissues. We also offer DAPI staining of tissue samples to evaluate apoptosis induction by compounds. Moreover, we also offer the study of the expression of different markers by Immunohistochemistry. Thus, we offer the evaluation of different cell death (PARP, Caspases, …) or proliferation (Ki67, Cyclins,…) markers. We can also offer the possibility to set up the evaluation of new markers of interest by the costumer.

Customer benefits

The costumer will benefit from the experience of the researchers involved in the service performing histological analyses of normal and tumor tissues. The service has also high expertise in immunohistochemistry staining and offers the possibility of setting up new antibodies that can be of interest for the costumer.

Target customer

The offered service can be of interest to research groups of academia or companies willing to study the histology of normal or tumor tissue samples.

References

  • Martínez-Torró C, Alba-Castellón L, Carrasco-Díaz LM, Serna N, Imedio L, Gallardo A, Casanova I, Unzueta U, Vázquez E, Mangues R, Villaverde A. Lymphocyte infiltration and antitumoral effect promoted by cytotoxic inflammatory proteins formulated as self-assembling, protein-only nanoparticles. Biomed Pharmacother. 2023 Aug;164:114976. doi: 10.1016/j.biopha.2023.114976.
  • Falgàs A, Garcia-León A, Núñez Y, Serna N, Sánchez-Garcia L, Unzueta U, Voltà-Durán E, Aragó M, Álamo P, Alba-Castellón L, Sierra J, Gallardo A, Villaverde A, Vázquez E, Mangues R, Casanova I. A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4+ lymphoma cells without toxicity in immunocompromised and immunocompetent mice. Biomed Pharmacother. 2022 Jun;150:112940. doi: 10.1016/j.biopha.2022.112940.
  • -Medina-Gutiérrez E, García-León A, Gallardo A, Álamo P, Alba-Castellón L, Unzueta U, Villaverde A, Vázquez E, Casanova I, Mangues R. Potent Anticancer Activity of CXCR4-Targeted Nanostructured Toxins in Aggressive Endometrial Cancer Models. Cancers (Basel). 2022 Dec 23;15(1):85. doi: 10.3390/cancers15010085.
  • Sala R, Rioja-Blanco E, Serna N, Sánchez-García L, Álamo P, Alba-Castellón L, Casanova I, López-Pousa A, Unzueta U, Céspedes MV, Vázquez E, Villaverde A, Mangues R. GSDMD-dependent pyroptotic induction by a multivalent CXCR4-targeted nanotoxin blocks colorectal cancer metastases. Drug Deliv. 2022 Dec;29(1):1384-1397. doi: 10.1080/10717544.2022.2069302.
  • Pallarès V, Unzueta U, Falgàs A, Aviñó A, Núñez Y, García-León A, Sánchez-García L, Serna N, Gallardo A, Alba-Castellón L, Álamo P, Sierra J, Cedó L, Eritja R, Villaverde A, Vázquez E, Casanova I, Mangues R. A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model. Biomaterials. 2022 Jan;280:121258. doi: 10.1016/j.biomaterials.2021.121258.
• Read More

U18-S04. In vitro Antitumor Activity

In vitro Antitumor Activity

The aim of this service is to evaluate the in vitro antitumor activity of compounds in different types of human cancer cell lines in which we determine the effect using different types of assays including MTT, LDH release and caspase activation. The cellular models that we offer include human cell lines from different tumor types including hematologic and solid neoplasias.

Customer benefits

The costumer will benefit from more than 20 years of experience of the researchers involved in the service that have performed the in vitro evaluation of the antitumor activity of different nanoparticles and other types of compounds.  We offer also the possibility of setting up new in vitro assays or to offer other cellular models that could be of interest for the costumer. Moreover, the conditions of the assays are flexible and will be adapted to the needs of each specific compound.

Target customer

The offered service can be of interest to research groups of academia or companies willing to test the antitumor activity of any compound in vitro.

References

  • Falgàs A, Pallarès V, Unzueta U, Núñez Y, Sierra J, Gallardo A, Alba-Castellón L, Mangues MA, Álamo P, Villaverde A, Vázquez E, Mangues R, Casanova I. Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells. Int J Nanomedicine. 2021 Mar 5;16:1869-1888. doi: 10.2147/IJN.S289733.
  • Núñez Y, Garcia-León A, Falgàs A, Serna N, Sánchez-García L, Garrido A, Sierra J, Gallardo A, Unzueta U, Vázquez E, Villaverde A, Mangues R, Casanova I. T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo. Pharmaceutics. 2023 Feb 22;15(3):727. doi: 10.3390/pharmaceutics15030727.
  • -Medina-Gutiérrez E, García-León A, Gallardo A, Álamo P, Alba-Castellón L, Unzueta U, Villaverde A, Vázquez E, Casanova I, Mangues R. Potent Anticancer Activity of CXCR4-Targeted Nanostructured Toxins in Aggressive Endometrial Cancer Models. Cancers (Basel). 2022 Dec 23;15(1):85. doi: 10.3390/cancers15010085.
  • Sala R, Rioja-Blanco E, Serna N, Sánchez-García L, Álamo P, Alba-Castellón L, Casanova I, López-Pousa A, Unzueta U, Céspedes MV, Vázquez E, Villaverde A, Mangues R. GSDMD-dependent pyroptotic induction by a multivalent CXCR4-targeted nanotoxin blocks colorectal cancer metastases. Drug Deliv. 2022 Dec;29(1):1384-1397. doi: 10.1080/10717544.2022.2069302.
• Read More

U18-S03. In vivo antitumor activity

In vivo antitumor activity

The aim of this service is to evaluate the biodistribution and/or the in vivo antitumor activity of nanoparticles and drug-loaded nanoparticles. Thus, we offer different tumor mouse models, subcutaneous and orthotopic, in which we can determine the biodistribution of nanoparticles, with or without loaded drug, in normal and tumor tissues. Moreover, we can also determine the antitumor activity of the compounds in different tumor models. In the service we have subcutaneous and orthotopic/disseminated models of lymphoma, leukemia and colorectal, endometrium, head and neck carcinomas. Moreover, we have also available PDX models of colorectal and endometrium cancer. We can also offer the possibility to set up new animal models of other tumor types.

Customer benefits

The customer will benefit from the experience of the researchers involved in the service that have performed the in vivo evaluation of a high number of diverse nanoparticles. The service has also high expertise in developing new cancer animal models. Thus, we offer also the possibility of setting up new models of any cancer type that fit with the needs of the costumer. Moreover, the conditions of the assays are flexible and will be adapted to the need of each specific compound.

Target customer

The offered service can be of interest to research groups of academia or companies willing to test the antitumor activity of nanoparticles or drug-loaded nanoparticles in vivo.

References

  • Martínez-Torró C, Alba-Castellón L, Carrasco-Díaz LM, Serna N, Imedio L, Gallardo A, Casanova I, Unzueta U, Vázquez E, Mangues R, Villaverde A. Lymphocyte infiltration and antitumoral effect promoted by cytotoxic inflammatory proteins formulated as self-assembling, protein-only nanoparticles. Biomed Pharmacother. 2023 Aug;164:114976. doi: 10.1016/j.biopha.2023.114976.
  • Rioja-Blanco E, Arroyo-Solera I, Álamo P, Casanova I, Gallardo A, Unzueta U, Serna N, Sánchez-García L, Quer M, Villaverde A, Vázquez E, Mangues R, Alba-Castellón L, León X. Self-assembling protein nanocarrier for selective delivery of cytotoxic polypeptides to CXCR4+ head and neck squamous cell carcinoma tumors. Acta Pharm Sin B. 2022 May;12(5):2578-2591. doi: 10.1016/j.apsb.2021.09.030.
  • Falgàs A, Garcia-León A, Núñez Y, Serna N, Sánchez-Garcia L, Unzueta U, Voltà-Durán E, Aragó M, Álamo P, Alba-Castellón L, Sierra J, Gallardo A, Villaverde A, Vázquez E, Mangues R, Casanova I. A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4+ lymphoma cells without toxicity in immunocompromised and immunocompetent mice. Biomed Pharmacother. 2022 Jun;150:112940. doi: 10.1016/j.biopha.2022.112940.
  • -Medina-Gutiérrez E, García-León A, Gallardo A, Álamo P, Alba-Castellón L, Unzueta U, Villaverde A, Vázquez E, Casanova I, Mangues R. Potent Anticancer Activity of CXCR4-Targeted Nanostructured Toxins in Aggressive Endometrial Cancer Models. Cancers (Basel). 2022 Dec 23;15(1):85. doi: 10.3390/cancers15010085.
  • Sala R, Rioja-Blanco E, Serna N, Sánchez-García L, Álamo P, Alba-Castellón L, Casanova I, López-Pousa A, Unzueta U, Céspedes MV, Vázquez E, Villaverde A, Mangues R. GSDMD-dependent pyroptotic induction by a multivalent CXCR4-targeted nanotoxin blocks colorectal cancer metastases. Drug Deliv. 2022 Dec;29(1):1384-1397. doi: 10.1080/10717544.2022.2069302.
  • Serna N, Falgàs A, García-León A, Unzueta U, Núñez Y, Sánchez-Chardi A, Martínez-Torró C, Mangues R, Vazquez E, Casanova I, Villaverde A. Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid Materials. Pharmaceutics. 2022 Jan 14;14(1):192. doi: 10.3390/pharmaceutics14010192.
  • Pallarès V, Unzueta U, Falgàs A, Aviñó A, Núñez Y, García-León A, Sánchez-García L, Serna N, Gallardo A, Alba-Castellón L, Álamo P, Sierra J, Cedó L, Eritja R, Villaverde A, Vázquez E, Casanova I, Mangues R. A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model. Biomaterials. 2022 Jan;280:121258. doi: 10.1016/j.biomaterials.2021.121258.
• Read More

Prof. Ramón Martínez, Director of NANBIOSIS, has been awarded the Spanish National Research Prize

Prof. Ramón Martínez Máñez wins the 2024 National Research Award for his work in nanotechnology, drug delivery systems, and biomedical, environmental sensors.

Valencia, october 2024. Prof. Martínez Máñez has been honored with the “Juan de la Cierva” National Research Award for the impact of his scientific career and its transfer in the field of chemistry, specifically in nanotechnology for controlled release systems and their use in sensors for medical, environmental, and agricultural applications.

The evaluators also highlighted the high number of patents obtained and licensed by the awardee and emphasized the number of companies he has created, one of which was among the first focused on the development of senolytics.

In additon of being deeply invested in NANBIOSIS, Ramón Martínez Máñez is Professor at the Universitat Politècnica de València (UPV) and director of the Inter-University Institute for Molecular Recognition and Technological Development Research (IDM, a joint UPV-UV center).

“Receiving this award is a great recognition of the work carried out over many years in the field of research and transfer, which would not have been possible without the support of my research group. It is also a great boost to continue striving and improving every day.”

— Prof. Ramón Martínez Máñez

“Receiving this award is a great recognition of the work carried out over many years in the field of research and transfer, which would not have been possible without the support of my research group. It is also a great boost to continue striving and improving every day,” said Ramón Martínez Máñez.

Prof. Ramón Martínez Máñez, professor at Universitat Politècnica de València (UPV), is the Director of NANBIOSIS and is leading, together with Prof. Salvador Gil, our Unit 26. This Unit is specialized in NMR, and can acquire unique metabolic profiles of biofluids, cell lines, tissues and animal models such as mice and rats.

Regarding his upcoming challenges, the UPV professor and researcher highlighted three: continuing to advance in the development of new sensors and nanomaterials, promoting the application of research either in collaboration with companies or through the creation of spin-offs, and continuing their work in training new researchers.

“All of these are key to continuing to advance in this exciting world of science and contributing to its progress in our country, from our laboratories at the Universitat Politècnica de València,” added Ramón Martínez Máñez.

Part of the team at our Unit 26. Left ot right: Mustafa Ezzeddin Ayoub, Dr. Salvador Gil and Prof. Ramón Martínez Máñez.

About Prof. Ramón Martínez Máñez

Born in Valencia on April 11, 1963, Martínez Máñez is one of the national and international leaders in the field of chemical research.

Among other lines of research, his group at the IDM Institute of UPV works on the development of nanometric devices with “molecular gates” for the controlled release of drugs. The studied nanoparticles are capable of retaining a load within their pore system and delivering it upon receiving a chemical, physical, or biochemical stimulus. These particles have been used, for example, for the selective release of cytotoxins to eliminate cancer cells and bacteria, as well as for the release of specific drugs in senescent cells, and for the release of substances in food or agricultural applications.

Additionally, Martínez Máñez’s team is working on the development of molecular probes for the detection, through color and fluorescence changes, of biomedical and environmental elements of interest, such as certain biomarkers or cells, drugs, nerve gases, etc.

Among the multiple recognitions he has received prior to this National Research Award, in 2016 he was honored with the Research Excellence Award from the Spanish Royal Society of Chemistry (RSEQ), and in 2018 with the Rey Jaume I Award for New Technologies.

Author of nearly 600 publications, Ramón Martínez Máñez has a prominent presence in the most significant journals in the field of multidisciplinary chemistry.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

Knowdlege growth: A chart-guide for cloning, production, purification, and characterization of recombinant proteins from prokaryotic systems

The Nanobiotechnology Group and NANBIOSIS PPP have created a poster-guide for recombinant protein cloning, production, and purification in prokaryotic systems.

Barcelona, october 2024. The Nanobiotechnology Group, led by Prof. Villaverde, in collaboration with the NANBIOSIS Unit 1, Protein Production Platform (PPP), directed by Dr. Ferrer-Miralles, has created an in-depth guide in the form of a poster that compiles key strategies for cloning, production, purification, and characterization of recombinant proteins expressed in prokaryotic systems.

Drawing from their vast experience in the field, they have meticulously outlined techniques and best practices to address common challenges and optimize every stage of the process. The poster covers various aspects of recombinant protein workflow, including selecting the right expression vectors, optimizing culture conditions, purification strategies, and the essential steps for characterizing the final purified protein.

The poster is displayed at the PPP facilities for easy consultation by anyone interested and is also available in the platform website to provide wider support to scientists in overcoming common challenges in the recombinant protein field.

The development of this poster reflects the collective expertise of the Nanobiotechnology Group and PPP in the field of recombinant proteins, gained through years of hands-on research.

The development of this poster reflects the collective expertise of the Nanobiotechnology Group and PPP in the field of recombinant proteins, gained through years of hands-on research. Understanding the critical role that recombinant proteins play in fields ranging from drug development to bioengineering they aim to equip researchers with the tools they have found useful for troubleshooting challenges in recombinant protein production.

The doors of the PPP are always open to provide guidance and technical support, if necessary, to the entire scientific community in the successful isolation of highly pure, soluble, stable, and active recombinant proteins, not only in procaryotic expression systems, but also using mammalian and insect cells.

Download full guide in PDF (free of charge)

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More